BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32164171)

  • 1. Functional Classification of
    Dutta S; Pregartner G; Rücker FG; Heitzer E; Zebisch A; Bullinger L; Berghold A; Döhner K; Sill H
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32164171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis.
    Qin G; Han X
    Transfus Med Hemother; 2023 Jun; 50(3):234-244. PubMed ID: 37435002
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Shin DY
    Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of subclonal
    Prochazka KT; Pregartner G; Rücker FG; Heitzer E; Pabst G; Wölfler A; Zebisch A; Berghold A; Döhner K; Sill H
    Haematologica; 2019 Mar; 104(3):516-523. PubMed ID: 30309854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts.
    Shen K; Hu DY; Zhang ZB; Guo YS; Zhang FH; Chen SN
    Int J Lab Hematol; 2023 Jun; 45(3):344-352. PubMed ID: 36860196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
    Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent prognostic significance of TP53 mutations in adult acute myeloid leukaemia with complex karyotype.
    Xu N; Lai YY; Chen WM; Jiang H; Wang Y; Wang X; Zhao XS; Huang XJ; Jiang Q; Qin YZ
    Int J Lab Hematol; 2022 Oct; 44(5):892-899. PubMed ID: 35505580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with
    Patel SA; Cerny J; Gerber WK; Ramanathan M; Ediriwickrema A; Tanenbaum B; Hutchinson L; Meng X; Flahive J; Barton B; Gillis-Smith AJ; Suzuki S; Khedr S; Selove W; Higgins AW; Miron PM; Simin K; Woda B; Gerber JM
    EJHaem; 2023 Nov; 4(4):1059-1070. PubMed ID: 38024632
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
    Zhao D; Eladl E; Zarif M; Capo-Chichi JM; Schuh A; Atenafu E; Minden M; Chang H
    Cancer Med; 2023 Mar; 12(6):6511-6522. PubMed ID: 36394085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survival efficacy of MDS/AML patients with TP53 abnormal received allogeneic hematopoietic stem cell transplantation].
    Feng D; Wang MY; Liu J; Zhang HX; Chen X; Zhang RL; Zhai WH; Ma QL; Pang AM; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):222-229. PubMed ID: 37356984
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characteristics of acute myeloid leukemia and the dismal prognosis of
    Liu H; Shi Y; Tao S; Li Y; Wang C; Yu L
    Hematology; 2023 Dec; 28(1):2223866. PubMed ID: 37313982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
    Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
    Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
    Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
    Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.